A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia |
| |
Authors: | U. Hauf-Zachariou L. Widmann B. Zülsdorf M. Hennig P. D. Lang |
| |
Affiliation: | (1) Department of Clinical Research, Boehringer Mannheim GmbH, Mannheim, Germany;(2) Department of Biometrics, Boehringer Mannheim GmbH, Mannheim, Germany |
| |
Abstract: | Summary We have studied 250 patients with mild to moderate essential hypertension (diastolic blood pressure 95 – 114 mmHg) and dyslipidaemia (high-density lipoprotein cholesterol (HDL-C) below 1.03 mmol·l–1, total cholesterol 5.17–9.05 mmol·l–1, and triglycerides 2.26–5.64 mmol·l–1) in a controlled double-blind, multicentre, parallel group trial.The patients took a fat-modified diet. After a 4-week placebo period, patients who continued to fulfil the selection criteria were randomly allocated to treatment with either carvedilol (a vasodilating -blocker) 25–50 mg o.d. (n=116) or captopril (an ACE inhibitor) 25–50 mg o.d. (n=117) for 6 months.In both groups there were favourable effects on the serum lipids. The relative changes (medians) in the carvedilol and captopril group were respectively: increase in HDL-C by 11% and 8%, decrease in total cholesterol by 11% and 10%, in low-density lipoprotein cholesterol by 16% and 12%, and in triglycerides by 13% and 14%. Equivalence of the two treatments was confirmed for the target variable change in HDL-C at a significance level of 5%.Reductions in supine systolic/diastolic blood pressures were comparable in the two groups (carvedilol: 23/19 mmHg, captopril: 20/18 mmHg).The improvement in lipid metabolism in patients treated with carvedilol is probably due to its 1-blocking properties. |
| |
Keywords: | Dyslipidaemia Hypertension Captopril Carvedilol lipids diet |
本文献已被 SpringerLink 等数据库收录! |
|